Myriad Genetics Inc., the maker of tests for hereditary risks of breast and ovarian cancer that lost its patent fight at the U.S. Supreme Court last year, failed to convince a federal court to block a competitor from selling its own genetic tests while another patent-infringement case is pending.
Myriad had asked U.S. District Judge Robert Shelby in Salt Lake City to issue a preliminary injunction to stop Ambry Genetics Corp. from offering its tests while the lawsuit against the company, University of Utah Research Foundation v. Ambry Genetics, is pending. But on Monday the judge issued a 106-page decision in which he said Myriad is unlikely to win lawsuits claiming tests sold by Ambry violate its patents.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
